Search

ISSN: 2228-5881 eISSN: 2251-7308

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Indexing Info About APB & Contacts Indexing and Abstracting Articles In Press Archive

Journal Info:

Freq.: Quarterly

eISSN: 2251-7308
pISSN: 2228-5881

Permission: CC By

Platinum Open Access

(no submission or publication fees)

Powered by

Abstracting and Indexing

PubMed Central, Pubmed,

Emerging Sources Citation Index

Scopus, Google Scholar,

EMBASE/Excerpta Medica

EBSCOhost; CAS: DOAJ

SCImago Journal & Country Rank

2024, Vol 14, No. 4

Advanced Pharmaceutical Bulletin (APB) is a peer-reviewed multidisciplinary open access journal, covering a wide range of various integrative fields with Pharmaceutical sciences.
APB is the official journal of Drug Applied Research Center and Faculty of Pharmacy, published by TUOMS PRESS, Tabriz University of Medical Sciences.

Publication Advantages in Advanced Pharmaceutical Bulletin are:

Free of charge publication for all types of articles
Fast and constructive peer review
Easy and quick online submission of manuscripts
Author friendly review
Rapid publication by means of running issue concept, which gives authors the benefit of 'No Waiting Time' for the officially accepted manuscripts
Free publication of color images
Worldwide visibility of papers (Open Access Journal)

Original Research

1. Preparation, Evaluation and Optimization of Multiparticulate System of Mebendazole for Colon Targeted Drug Delivery by Using Natural Polysaccharides

Kuldeep Hemraj Ramteke*, Varsha Balaji Jadhav, Nilesh Shrikant Kulkarni, Amol Rameshrao Kharat, Sonali Bhima Diwate

Adv Pharm Bull. 2015;5(3): 361-371. doi: 10.15171/apb.2015.050

PMCID: PMC4616903 PMID: 26504758 Scopus ID: 84983584997

Article

PDF

XML

Cited By:

14

1

12

Review Article

2. The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering

Abbas Mohajeri, Sarvin Sanaei, Farhad Kiafar, Amir Fattahi, Majid Khalili, Nosratollah Zarghami*

Adv Pharm Bull. 2017;7(1): 21-34. doi: 10.15171/apb.2017.004

PMCID: PMC5426730 PMID: 28507934 Scopus ID: 85017542839

Article

PDF

XML

Cited By:

14

10

16

Research Article

3. Two Simple Methods for Optimizing the Production of “Difficult-to-Express” GnRH-DFF40 Chimeric Protein

Mahdi Barazesh , Zohreh Mostafavipour , Soudabeh Kavousipour, Shiva Mohammadi , Pooneh Mokarram*

Adv Pharm Bull. 2019;9(3): 423-431. doi: 10.15171/apb.2019.050

PMCID: PMC6773931 PMID: 31592077 Scopus ID: 85070463403

Article

PDF

XML

Cited By:

3

1

3

Research Article

4. Lysine Decorated Solid Lipid Nanoparticles of Epirubicin for Cancer Targeting and Therapy

Parvaneh Bayat , Parvaneh Pakravan* , Mojtaba Salouti, Jafar Ezzati Nazhad Dolatabadi

Adv Pharm Bull. 2021;11(1): 96-103. doi: 10.34172/apb.2021.010

PMCID: PMC7961234 PMID: 33747856 Scopus ID: 85096971330

Article

PDF

Full Text

XML

Cited By:

7

4

16

Research Article

5. Bioinformatics and In Vitro Studies Reveal the Importance of p53, PPARG and Notch Signaling Pathway in Inhibition of Breast Cancer Stem Cells by Hesperetin

Adam Hermawan* , Muthi Ikawati, Annisa Khumaira, Herwandhani Putri, Riris Istighfari Jenie, Sonia Meta Angraini, Haruma Anggraini Muflikhasari

Adv Pharm Bull. 2021;11(2): 351-360. doi: 10.34172/apb.2021.033

PMCID: PMC8046396 PMID: 33880358 Scopus ID: 85103187034

Article

PDF

Suppl 1

Full Text

XML

Cited By:

7

7

3

Review Article

6. Understanding Hyaluronan Receptor (CD44) Interaction, HA-CD44 Activated Potential Targets in Cancer Therapeutics

Gul-e-Saba Chaudhry* , Abdah Akim, Muhammad Naveed Zafar, Naila Safdar, Yeong Yik Sung, Tengku Sifzizul Tengku Muhammad

Adv Pharm Bull. 2021;11(3): 426-438. doi: 10.34172/apb.2021.050

PMCID: PMC8421618 PMID: 34513617 Scopus ID: 85108917744

Article

PDF

Full Text

XML

Cited By:

6

12

39

Review Article

7. Erythrocytes Nanoparticle Delivery: A Boon for Targeting Tumor

Adnan Rehmatullah Siddique* , Geeta Sameer Bhagwat

Adv Pharm Bull. 2024;14(1): 132-146. doi: 10.34172/apb.2023.080

PMCID: PMC10997934 PMID: 38585450

Article

PDF

Full Text

XML

Cited By:

0

Review Article

8. Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy

Joan Onyebuchi Erebor* , Elizabeth Oladoyin Agboluaje , Ava M. Perkins , Megha Krishnakumar, Ndidi Ngwuluka

Adv Pharm Bull. 2024;14(3): 558-573. doi: 10.34172/apb.2024.046

PMCID: PMC11530881 PMID: 39494247

Article

PDF

Full Text

XML

Cited By:

0

Editorial

9. Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications

Daohong Chen*

Adv Pharm Bull. 2024;14(4): 737-744. doi: 10.34172/apb.43306

Article

PDF

Full Text

XML

Cited By:

0